Please provide your email address to receive an email when new articles are posted on . The FDA today approved epoetin alfa-epbx, the first epoetin alfa biosimilar, for the treatment of anemia caused ...

The anemia drugs epoetin alfa (Procrit and Epogen) and darbepoetin alfa (Aranesp) are among the top-sellers in the U.S., as consumers and their insurance companies spent $7.2 billion in 2008 on this ...

The Food and Drug Administration (FDA) approved Retacrit (epoetin alfa-epbx), a biosimilar of Epogen/Procrit (epoetin alfa), to treat anemia caused by a number of factors – including undergoing ...

The US Food and Drug Administration (FDA) has approved the first biosimilar erythropoiesis-stimulating agent. The reference product is epoetin alfa (Epogen/Procrit, Amgen). The new biosimilar is ...

Johnson & Johnson said some of its Procrit anemia treatment was found diluted to greatly reduce the amount of active medicine in the solution, the latest in a string of drug counterfeiting incidents ...

The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, ...

When it comes to defending its anemia drug business, Amgen Inc. of Thousand Oaks is betting that less is more. Over the weekend, the biotech giant released data from a large clinical trial suggesting ...

Decisions by major central banks this week brought the end of pandemic-era monetary policy into closer view, but also highlighted how long the road back to "normal" will be as officials now probe for ...